These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1069 related articles for article (PubMed ID: 6747294)

  • 1. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of C1 activation by nascent C3b and C4b: a mechanism of feedback inhibition.
    Ziccardi RJ
    J Immunol; 1986 May; 136(9):3378-83. PubMed ID: 3485688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
    Takata Y; Tamura N; Fujita T
    J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of immune precipitation by complement.
    Schifferli JA; Bartolotti SR; Peters DK
    Clin Exp Immunol; 1980 Nov; 42(2):387-94. PubMed ID: 6781802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of immune precipitation by purified components of the alternative pathway.
    Naama JK; Holme E; Hamilton E; Whaley K
    Clin Exp Immunol; 1985 Apr; 60(1):169-77. PubMed ID: 3159522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of classical pathway components during alternative pathway--modulated immune complex aggregation: the role of C1 INH.
    Gronski P; Bodenbender L; Kanzy EJ; Seiler FR
    Behring Inst Mitt; 1984 Nov; (76):29-41. PubMed ID: 6335396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of C1, C1-inactivator and C4 in modulating immune precipitation.
    Schifferli JA; Steiger G; Schapira M
    Clin Exp Immunol; 1985 Jun; 60(3):605-12. PubMed ID: 4017288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
    Corvetta A; Spaeth PJ; Ghirelli PA; Orecchioni F; Buetler R; Montroni M; Nydegger UE
    Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of immune precipitation by purified classical pathway complement components.
    Naama JK; Hamilton AO; Yeung-Laiwah AC; Whaley K
    Clin Exp Immunol; 1984 Nov; 58(2):486-92. PubMed ID: 6333948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of covalently linked C3-C3 dimers on IgG immune aggregates.
    Barrio E; Antón LC; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1991 Feb; 21(2):343-9. PubMed ID: 1999223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F; Kijlstra A
    Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement mediated inhibition of immune precipitation and solubilization generate different concentrations of complement anaphylatoxins (C4a, C3a, C5a).
    Schifferli JA; Steiger G; Paccaud JP
    Clin Exp Immunol; 1986 May; 64(2):407-14. PubMed ID: 3488858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of immune complexes by the classical pathway.
    Whaley K; Ahmed AE
    Behring Inst Mitt; 1989 Jul; (84):111-20. PubMed ID: 2529842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways.
    Schifferli JA; Woo P; Peters DK
    Clin Exp Immunol; 1982 Mar; 47(3):555-62. PubMed ID: 6979442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral immunostimulation. IV. Role of complement.
    Shearer WT; Atkinson JP; Frank MM; Parker CW
    J Exp Med; 1975 Apr; 141(4):736-52. PubMed ID: 1168690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetanus toxoid-anti-tetanus toxoid complexes: a potential model to study the complement transport system for immune complex in humans.
    Paccaud JP; Steiger G; Sjöholm AG; Spaeth PJ; Schifferli JA
    Clin Exp Immunol; 1987 Aug; 69(2):468-76. PubMed ID: 2958199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
    Doekes G; van Es LA; Daha MR
    Immunology; 1983 Jun; 49(2):215-22. PubMed ID: 6852866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C3 binds with similar efficiency to Fab and Fc regions of IgG immune aggregates.
    Antón LC; Ruiz S; Barrio E; Marqués G; Sánchez A; Vivanco F
    Eur J Immunol; 1994 Mar; 24(3):599-604. PubMed ID: 8125130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.